XML 34 R2.htm IDEA: XBRL DOCUMENT v3.6.0.2
Balance Sheets - USD ($)
Dec. 31, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 7,507,659 $ 3,293,983
Short-term investments available-for-sale, at fair value 4,304,901 28,201,507
Accounts receivable 1,377,441 716,246
Inventory, net of allowance of $270,307 at December 31, 2016 and $284,319 at December 31, 2015 1,511,053 2,201,301
Prepaid expenses and other 433,328 445,217
Total current assets 15,134,382 34,858,254
Long-term investments available-for-sale, at fair value   2,603,901
Deferred offering costs 49,630  
Property and equipment, net 3,270,197 1,932,213
Total assets 18,454,209 39,394,368
Current liabilities:    
Accounts payable 761,663 724,805
Accrued liabilities 1,670,286 1,915,268
Deferred revenue, current portion 335,659 47,476
NuvoGen obligation 604,751 543,750
Term loan 6,389,782 3,059,068
Other current liabilities 258,850 29,243
Total current liabilities 10,020,991 6,319,610
Term loan payable - non-current, net of discount and debt issuance costs 5,389,137 7,737,586
NuvoGen obligation - non-current, net of discount 8,017,356 8,415,122
Other 619,587 28,652
Total liabilities 24,047,071 22,500,970
Commitments and Contingencies
Stockholders’ equity (deficit):    
Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2016, and December 31, 2015, 7,939,967 and 7,938,571 shares issued and outstanding, respectively, at December 31, 2016, 6,845,638 and 6,844,242 shares issued and outstanding, respectively, at December 31, 2015 7,938 6,844
Additional paid-in-capital 110,081,334 106,569,405
Treasury stock – 1,396 shares, at cost (75,000) (75,000)
Accumulated other comprehensive loss (1,090) (41,357)
Accumulated deficit (115,606,044) (89,566,494)
Total stockholders’ equity (deficit) (5,592,862) 16,893,398
Total liabilities and stockholders' equity (deficit) $ 18,454,209 $ 39,394,368